March 5 (Reuters) - Sepracor Inc:
* Reports preliminary Phase II study results for September-225441 for the
treatment of generalized anxiety disorder
* Says study did not meet its primary efficacy endpoint
* Says in the process of further analyzing data in an effort to determine
whether any of secondary endpoints were met
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Reports preliminary Phase II study results for September-225441 for the
treatment of generalized anxiety disorder
* Says study did not meet its primary efficacy endpoint
* Says in the process of further analyzing data in an effort to determine
whether any of secondary endpoints were met
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.